Does Sotorasib work for stage 4 cancer without KRAS mutations?

This is such an important question about treatment options. Sotorasib (brand name Lumakras) is specifically designed to target the KRAS G12C mutation, so it typically works best for patients who have this specific genetic change. For those without KRAS mutations, the effectiveness would likely be very limited since the drug targets that particular pathway. Having detailed genetic testing and discussing all available treatment options with an oncology team can help identify the most promising therapies based on specific tumor characteristics and mutation profile.